Accessibility StatementSkip Navigation Search for successor underway DALLAS, Sept. 10, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced that Executive Vice President - Finance and Chief Financial Officer Don Newman has informed the Company he will retire March 1, 2026. As the Company conducts a search for his successor, Newman will continue to serve as Chief Financial Officer until his retirement date. Following his retirement, he will serve the Company in an advisory capacity for a period of time ...

HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical, Biological, Radiological and Nuclear (“CBRN”) Conference, taking place September 8–10, 2025, in Switzerland. Dr. Gelhaus will join NATO and allied representative ...

- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T ...

Core Viewpoint - Altai Resources Inc. is facing significant legal challenges and financial burdens due to a claim against the Government of Quebec regarding the expropriation of its oil and gas exploration assets in 2022, leading the company to abandon its legal representation as it deems further pursuit of justice futile [1][5]. Group 1: Legal Proceedings - The company filed a claim in the Superior Court of Quebec in 2022 against the Ministry of Energy and Natural Resources and the Attorney General of Quebec for compensatory damages due to expropriation [1]. - Progress in the legal proceedings has been significantly delayed since the company's case was joined with other similar actions, with no hearing date set for the first phase [2]. - The company proposed advancing certain test cases to streamline the process, but this approach was rejected by the defendants, leading to concerns about escalating legal costs [3]. Group 2: Financial Implications - The company has incurred considerable legal costs and is facing a motion from the defendants seeking security for costs amounting to $250,000, which could further strain its financial resources [4]. - The company believes that the ongoing litigation and the defendants' tactics will continue to impose a crippling financial burden, prompting the decision to abandon legal representation to protect its working capital [5]. Group 3: Company Overview - Altai Resources Inc. is based in Toronto, Ontario, and has an oil property in Alberta along with a Canadian investment portfolio consisting of cash and cash equivalents [6].

Core Points - Altai Resources Inc. has announced a special cash distribution of $0.06 per common share, totaling approximately $3.4 million, following shareholder approval for a reduction of the stated capital account [1][2] - The special cash distribution will be paid to holders of common shares recorded by October 2, 2025, with payment scheduled for October 9, 2025 [2] - The common shares will trade on a "due bill" basis starting October 3, 2025, and will trade "ex-distribution" from October 10, 2025 [2] Company Overview - Altai Resources Inc. is based in Toronto, Ontario, and has an oil property in Alberta along with a Canadian investment portfolio consisting of cash and cash equivalents [3]

Group 1 - Altai Resources Inc. announced that shareholders approved a special resolution for a reduction of the stated capital account of the common shares by up to a maximum cumulative total amount of $4,000,000 [1] - Approximately 96.4% of the votes cast at the special meeting were in favor of the Stated Capital Reduction Resolution [1] - The purpose of the capital reduction is to distribute the approved amount to holders of common shares through one or more special cash distributions [1] Group 2 - Altai Resources Inc. is based in Toronto, Ontario, and has an oil property in Alberta along with a Canadian investment portfolio consisting of cash and cash equivalents [2]

Group 1 - Altai Resources Inc. has sold its 50% working interest in the Malartic Gold Property in Quebec to Globex Mining Enterprises Inc. for a cash consideration of $142,000 [1] - The sale price represents a premium of $18,289, approximately 15%, over the carrying value of the property as per the latest interim financial statements [1] Group 2 - Altai Resources Inc. is based in Toronto, Ontario, and has an oil property in Alberta along with a Canadian investment portfolio consisting of cash and cash equivalents [2]

Core Insights - Mesirow acted as the exclusive financial advisor to ATI on the sale of its East Hartford Operations to Barnes Aerospace, highlighting Mesirow's expertise in the aerospace and defense sector [1][8] - The East Hartford Operations specializes in machining flight-safety critical rotating hardware, serving both commercial and defense aerospace sectors [1][6] Company Overview - ATI is a global producer of high-performance materials and solutions for aerospace, defense, electronics, medical, and specialty energy markets [1] - The East Hartford Operations has over 75 years of operational history and is recognized for its quality products and customer service [2][6] Transaction Details - The transaction is part of Mesirow's successful track record in aerospace and defense corporate carve-out transactions, with over 350 transactions completed across various verticals [3] - Mesirow's deep industry expertise and long-standing client relationships contributed to the successful outcome of this transaction [3]

Core Insights - ATI Inc. reported a profit of $100.7 million or 70 cents per share for Q2 2025, an increase from $81.9 million or 58 cents in the same quarter last year, with adjusted earnings of 74 cents, up 23.3% year over year, surpassing the Zacks Consensus Estimate of 72 cents [1][10] Financial Performance - Net sales for Q2 2025 were $1,140.4 million, slightly below the Zacks Consensus Estimate of $1,144.3 million, but up approximately 4.1% year over year, driven by strong growth in aerospace and defense [2] - High-Performance Materials & Components (HPMC) segment reported sales of $608.8 million, an 8.3% increase year over year, although it missed the consensus estimate of $621.4 million; segment EBITDA rose 26.5% year over year to $144 million [3] - Advanced Alloys & Solutions (AA&S) recorded sales of $531.6 million, a slight decline of 0.3% from the previous year, but exceeded the consensus estimate of $525.2 million; segment EBITDA decreased by 12.3% year over year to $76.7 million [4] - Cash and cash equivalents stood at $319.6 million, down from $425.6 million the previous year, while long-term debt decreased by 7.7% to $1,710.7 million [5] Future Outlook - For Q3 2025, adjusted EBITDA is expected to be between $200 million and $210 million, with full-year guidance set between $810 million and $840 million; adjusted earnings per share are projected at 69-75 cents for Q3 and $2.90 to $3.07 for the full year [6][10] - Adjusted free cash flow for the full year is estimated to be between $270 million and $350 million, with anticipated capital expenditures between $260 million and $280 million [6]

Core Viewpoint - Appili Therapeutics has announced a peer-reviewed publication supporting the efficacy of its vaccine candidate ATI-1701 against tularemia, highlighting its robust protection in multiple animal models [1][2][3]. Company Overview - Appili Therapeutics is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, with a mission to address life-threatening infections [7]. - The company is advancing a diverse range of anti-infectives, including ATI-1701, which is aimed at preventing tularemia, a highly contagious bacterial disease [7]. Vaccine Candidate Details - ATI-1701 is a live attenuated strain of Francisella tularensis, being developed as a first-in-class vaccine for tularemia, which currently has no approved vaccine in major markets [2][5][6]. - The vaccine is considered a top biodefense priority due to the severe illness it can cause and its high infectiousness, being over 1,000 times more infectious than anthrax [6]. Study Findings - The publication details studies showing that ATI-1701 provided 100% survival in rats challenged with aerosolized SCHU S4 up to one year post-vaccination, even at doses exceeding 10,000 times the median lethal dose [8]. - In cynomolgus macaques, the vaccine demonstrated up to 100% protection, reduced disease severity, and improved histopathological outcomes, with robust antibody responses correlating with survival [8]. Development and Partnerships - The study reinforces ATI-1701's potential as a leading candidate for tularemia prevention and supports continued development in partnership with the U.S. Department of Defense [4].